Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis.

Ronza Najjar-DebbinyNaomi GronichGabriel WeberNili SteinWalid Saliba

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

This study suggests that Evusheld (150 mg Tixagevimab and 150 mg Cilgavimab) is effective in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalization in immunocompromised patients. The effectiveness of this dose appears to be greater in non-obese patients.

Keyphrases

end stage renal disease
newly diagnosed
obese patients
ejection fraction
chronic kidney disease
randomized controlled trial
systematic review
bariatric surgery
coronavirus disease
peritoneal dialysis
prognostic factors
sars cov
respiratory syndrome coronavirus